Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 557795-19-4 Chemical Structure| 557795-19-4

Structure of Sunitinib
CAS No.: 557795-19-4

Chemical Structure| 557795-19-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50 values of 80 nM for VEGFR2 and 2 nM for PDGFRβ. As an ATP-competitive inhibitor, Sunitinib effectively inhibits autophosphorylation of Ire1α, thereby preventing RNase activation.

Synonyms: SU 11248

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Marlhoux, Léna ; Arnaud, Alexandre ; Hervieu, Céline ; Makulyte, Gabriela ; Martinasso, Charlotte ; Mularoni, Angélique , et al.

Abstract: Casein kinase 2 (CK2) has emerged as a promising therapeutic target across a broad spectrum of malignancies, including pediatric and orphan cancers. The identification of a ligandable allosteric αD pocket on the CK2α subunit has enabled the development of bivalent inhibitors, which bind simultaneously to both the adenosine triphosphate (ATP) site and the allosteric pocket. Here, we report the discovery and pharmacological characterization of KDX1381, a structure-guided bivalent CK2α inhibitor with low-nanomolar potency and high selectivity, confirmed by cocrystal structures. In mice, KDX1381 suppressed CK2-driven tumor growth as a monotherapy and enhanced therapeutic efficacy when combined with vascular endothelial growth factor receptor (VEGFR) inhibitors or DNA-damaging agents in hepatocellular carcinoma and glioma models. These findings support bivalent CK2α inhibition as a differentiated therapeutic strategy with broad applicability in CK2-dependent cancers.

Alternative Products

Product Details of Sunitinib

CAS No. :557795-19-4
Formula : C22H27FN4O2
M.W : 398.47
SMILES Code : CCN(CCNC(C(C(C)=C1/C([H])=C(C2=O)/C3=C(N2)C=CC(F)=C3)=C(N1)C)=O)CC
Synonyms :
SU 11248
MDL No. :MFCD09260778
InChI Key :WINHZLLDWRZWRT-ATVHPVEESA-N
Pubchem ID :5329102

Safety of Sunitinib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H360-H372
Precautionary Statements:P201-P202-P260-P264-P270-P280-P308+P313-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of Sunitinib

RTK

Isoform Comparison

Biological Activity

Target
  • VEGFR2

    VEGFR2, IC50:80 nM

  • VEGFR2

    VEGFR2 , IC50:80 nM

  • PDGFRβ

    PDGFRβ, IC50:2 nM

  • PDGFRβ

    PDGFRβ , IC50:2 nM

  • c-Kit

In Vitro:

Cell Line
Concentration Treated Time Description References
CD8+ T cells 2.5 μM overnight Sunitinib inhibits Stat3 activity in CD8+ T cells PMC3017475
HMLER-FOXC2 cells 10 µM 7 days To test the effect of Sunitinib on mammosphere formation in HMLER-FOXC2 cells, results showed that Sunitinib significantly reduced mammosphere formation. PMC3602160
HMLER-Snail cells 10 µM 7 days To test the effect of Sunitinib on mammosphere formation in HMLER-Snail cells, results showed that Sunitinib significantly reduced mammosphere formation. PMC3602160
Human umbilical vein endothelial cells (HUVECs) 1 nM 9 days To evaluate the effect of Sunitinib on IL-36 or VEGF-A stimulated HUVECs angiogenesis, results showed that Sunitinib significantly inhibited IL-36 and VEGF-A induced angiogenesis PMC5834930
786-0 cells 2μM to 5μM Establishment of sunitinib-resistant cell line 786-0R and evaluation of its resistance to sunitinib. PMC4326587
786-0shRNA and 786-0shEZH2 cells 2μM, 4μM, 6μM, 8μM 48 h Evaluation of the effect of EZH2 knockdown on sunitinib sensitivity, results showed increased sensitivity to sunitinib after EZH2 knockdown. PMC4326587
786-O cells 100 μM 24 h To validate the impact of AA on Sunitinib's inhibition of ccRCC cell proliferation and invasion, results showed that AA enhanced the inhibitory effect of Sunitinib. PMC10352361
ACHN cells 100 μM 24 h To validate the impact of AA on Sunitinib's inhibition of ccRCC cell proliferation and invasion, results showed that AA enhanced the inhibitory effect of Sunitinib. PMC10352361

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C.B17/Icr-scid mice PNX0010 xenograft tumour model oral 40 mg/kg 5 days per week To examine the effect of a high-fat/high-cholesterol diet on the antitumour efficacy of Sunitinib, and found that the high-fat/high-cholesterol diet diminished the antitumour effect of Sunitinib PMC5418451
mice Renca renal cell carcinoma model oral 30-40 mg/kg once daily for up to 14 days Sunitinib combined with CD8+ T cell adoptive transfer significantly inhibited tumor growth and inhibited Stat3 activity PMC3017475
NOD/SCID mice HMLER-FOXC2 tumor model oral 40 mg/kg 5 days a week for 30 days To evaluate the effect of Sunitinib on HMLER-FOXC2 tumor growth and animal survival, results showed that Sunitinib significantly reduced tumor growth and extended event-free survival. PMC3602160
mice nude mice gavage feeding 40 mg/kg/mouse five times a week Establishment of sunitinib-resistant renal cell carcinoma cell lines PMC7226215
Mice RP-R-01 and RP-R-02 patient-derived ccRCC xenograft models Oral gavage 40 mg/kg 5 days/week, until tumor resistance Evaluation of the effect of sunitinib dose escalation on overcoming resistance in ccRCC xenograft models, results showed that dose escalation restored tumor sensitivity to sunitinib. PMC4326587

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00372775 Non-Small Cell Lung Cancer PHASE2 COMPLETED 2025-12-09 Pfizer Investigational Site, N... More >>orwalk, Connecticut, 06856, United States|Pfizer Investigational Site, Cocoa Beach, Florida, 32931, United States|Pfizer Investigational Site, Merritt Island, Florida, 32952, United States|Pfizer Investigational Site, Titusville, Florida, 32796, United States|Pfizer Investigational Site, Creve Coeur, Missouri, 63141, United States|Pfizer Investigational Site, St. Louis, Missouri, 63110-1094, United States|Pfizer Investigational Site, St. Louis, Missouri, 63110, United States|Pfizer Investigational Site, St. Peters, Missouri, 63376, United States|Pfizer Investigational Site, Basking Ridge, New Jersey, 07920, United States|Pfizer Investigational Site, Commack, New York, 11725, United States|Pfizer Investigational Site, New York, New York, 10022, United States|Pfizer Investigational Site, Sayre, Pennsylvania, 18840, United States|Pfizer Investigational Site, Austin, Texas, 78705, United States|Pfizer Investigational Site, Austin, Texas, 78745, United States|Pfizer Investigational Site, Austin, Texas, 78758, United States|Pfizer Investigational Site, Austin, Texas, 78759, United States|Pfizer Investigational Site, Round Rock, Texas, 78664, United States|Pfizer Investigational Site, Pessac, Be1 04495, 33604, France|Pfizer Investigational Site, Marseille Cedex 09, 13009, France|Pfizer Investigational Site, Saint-Priest en Jarez Cedex, 42271, France|Pfizer Investigational Site, Toulouse cedex 9, 31059, France|Pfizer Investigational Site, Bologna, 40139, Italy|Pfizer Investigational Site, Genova, 16132, Italy|Pfizer Investigational Site, Orbassano (TO), 10043, Italy|Pfizer Investigational Site, Roma, 00151, Italy|Pfizer Investigational Site, Madrid, 28046, Spain|Pfizer Investigational Site, Valencia, 46014, Spain Less <<
NCT00981890 Brain Metastases PHASE1 COMPLETED 2025-05-22 University Health Network, Pri... More >>ncess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT01121562 Pancreatic Neuroendocrine Tumo... More >>rs Less << PHASE2 COMPLETED 2025-11-13 Aichi Cancer Center Central Ho... More >>spital, Nagoya, Aichi, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Osaka Police Hospital, Osaka, Japan Less <<
NCT00299741 Prostate Cancer PHASE2 COMPLETED 2025-06-08 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel-Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT06032728 Renal Cell Carcinoma NOT_YET_RECRUITING 2033-10-01 -
NCT01069770 Clear Cell Renal Cell Carcinom... More >>a|Metastasis Less << PHASE2 UNKNOWN 2025-06-12 National Cancer Center, Goyang... More >>-si, Gyeonggi-do, 410-769, Korea, Republic of|Chungbuk University Hospital, Cheonju, 361-711, Korea, Republic of|Samsung Medical Center, Seoul, 137-710, Korea, Republic of Less <<
NCT03140176 Metastatic Renal Cell Carcinom... More >>a Less << TERMINATED 2022-01-22 Pierre Et Marie Curie Center, ... More >>Algers, 16005, Algeria|CAC Annaba, Annaba, Algeria|Hanene Djedi, Annaba, Algeria|Kasr Al Aini, Cairo, 11562, Egypt|National Cancer Institute, Cairo, 11796, Egypt|Demerdash Hospital, Cairo, Egypt|Kuwait Cancer Control Center, Kuwait City, 70653, Kuwait|Institut National D'Oncologie, Rabat, Morocco Less <<
NCT00864864 Glioblastoma|Brain Tumor EARLY_PHASE1 COMPLETED 2025-05-13 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States Less <<
NCT01829217 Lung Cancer PHASE2 COMPLETED 2025-01-18 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02214, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT00577382 Mucosal Lentiginous Melanoma|A... More >>cral Lentiginous Malignant Melanoma Less << PHASE2 COMPLETED 2025-08-14 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Washington University in St. Louis, St. Louis, Missouri, 63110, United States|Vanderbilt University, Nashville, Tennessee, 37212, United States Less <<
NCT02848768 Metastatic Clear Cell Renal Ce... More >>ll Carcinoma Less << COMPLETED - CHU de Rennes, Rennes, 35033, ... More >>France Less <<
NCT02071641 Metastatic Renal Cell Carcinom... More >>a Less << PHASE2 TERMINATED 2025-09-16 VU Medical Center, Amsterdam, ... More >>1081 HV, Netherlands Less <<
NCT01082809 Advanced Biliary Tract Adenoca... More >>rcinoma Less << PHASE2 COMPLETED 2025-02-12 Samsung Medical Center, Seoul,... More >> Korea, Republic of Less <<
NCT00859456 Sarcoma, Soft Tissue PHASE2 TERMINATED 2025-02-13 Columbia University Medical Ce... More >>nter, New York, New York, 10032, United States Less <<
NCT00056693 Neuroendocrine Tumors PHASE2 COMPLETED 2025-09-06 Pfizer Investigational Site, B... More >>irmingham, Alabama, 35233, United States|Pfizer Investigational Site, Birmingham, Alabama, 35294, United States|Pfizer Investigational Site, Los Angeles, California, 90033-0800, United States|Pfizer Investigational Site, Los Angeles, California, 90033, United States|Pfizer Investigational Site, San Francisco, California, 94115-1705, United States|Pfizer Investigational Site, Pinckneyville, Illinois, 62274, United States|Pfizer Investigational Site, Boston, Massachusetts, 02114, United States|Pfizer Investigational Site, Boston, Massachusetts, 02115, United States|Pfizer Investigational Site, Boston, Massachusetts, 02215, United States|Pfizer Investigational Site, St Louis, Missouri, 63110, United States|Pfizer Investigational Site, St. Louis, Missouri, 63110, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, 19111, United States Less <<
NCT03592199 Clear Cell Renal Cell Carcinom... More >>a Less << PHASE2 UNKNOWN 2022-12-11 Instituto do Cancer do Estado ... More >>de S?o Paulo, S?o Paulo, 01246000, Brazil Less <<
NCT01718327 Unresectable and Advanced Chol... More >>angiocarcinoma Less << PHASE2 COMPLETED 2016-11-17 H?pital Beaujon, Clichy, 92118... More >>, France|H?pital privé Jean Mermoz, Lyon, 69008, France|CHU La Timone, Marseille, 13005, France|H?pital Saint Antoine, Paris, 75012, France|Institut Mutualiste Montsouris, Paris, 75014, France|Institut Gustave Roussy, Villejuif, 94805, France Less <<
NCT02623127 Thymic Carcinoma PHASE2 COMPLETED 2025-10-18 Seoul National University Bund... More >>ang Hospital, Seongnam, 463-707, Korea, Republic of Less <<
NCT04076787 Metastatic Renal Cell Carcinom... More >>a Less << COMPLETED 2018-09-02 University of Calgary, Calgary... More >>, Alberta, P2N4N2, Canada Less <<
NCT01286896 Malignant Solid Tumour PHASE1 UNKNOWN 2025-12-11 The Netherlands Cancer Institu... More >>te - Antoni van Leeuwenhoek Hospital, Amsterdam, 1066CX, Netherlands Less <<
NCT00694096 Renal Cell Cancer PHASE1 COMPLETED 2025-09-14 Huntsman Cancer Institute, Sal... More >>t Lake City, Utah, 84112, United States Less <<
NCT01498835 Soft Tissue Sarcoma PHASE1 COMPLETED 2025-02-15 Helios Klinikum Bad Saarow, Ba... More >>d Saarow, 15526, Germany|University Medical Center Mannheim, Mannheim, 68167, Germany Less <<
NCT00535379 Glioblastoma Multiforme PHASE2 UNKNOWN 2025-01-11 LKH Feldkirch, Feldkirch, Aust... More >>ria|Medical University Innsbruck, Innsbruck, 6020, Austria|LNK Wagner-Jauregg, Linz, Austria|Paracelsus Medical University, Salzburg, 5020, Austria|Medical University Vienna, Vienna, Austria|Kaiser-Franz-Josef Spital Wien, Wien, Austria|University Hospital of Heidelberg, Heidelberg, Baden-Württemberg, 69120, Germany|University Hospital of Mannheim, Mannheim, Baden-Württemberg, 68167, Germany|University Hospital of Bonn, Bonn, Nordrhein-Westfalen, 53105, Germany|University Hospital of Berlin, Berlin, 13353, Germany Less <<
NCT03519542 Metastatic Renal Cell Carcinom... More >>a Less << COMPLETED 2025-07-18 Hospital Clínico Universitario... More >> de Santiago de Compostela, Santiago de Compostela, A Coru?a, 15706, Spain|Hospital Universitario central de Asturias, Oviedo, Asturias, 33011, Spain|Hospital Marqués de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital Universitarios de Burgos, Burgos, 09006, Spain|Hospital Universiario de León, León, 24080, Spain|Hospital Gregorio Mara?ón, Madrid, 28007, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28024, Spain|Hospital Clínico (Madrid), Madrid, 28040, Spain|Hospital 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Carlos Haya, Málaga, 29010, Spain|Hospital Clínico Lozano Blesa, Zaragoza, 50009, Spain Less <<
NCT00798889 Solid Tumors COMPLETED 2025-12-11 Pfizer Investigational Site, B... More >>irmingham, Alabama, 35233-2115, United States|Pfizer Investigational Site, Birmingham, Alabama, 35233, United States|Pfizer Investigational Site, Birmingham, Alabama, 35294, United States|Pfizer Investigational Site, Los Angeles, California, 90033, United States|Pfizer Investigational Site, Los Angeles, California, 90095, United States|Pfizer Investigational Site, San Francisco, California, 94115-1705, United States|Pfizer Investigational Site, San Francisco, California, 94115, United States|Pfizer Investigational Site, Santa Monica,, California, 90404, United States|Pfizer Investigational Site, Aurora, Colorado, 80045, United States|Pfizer Investigational Site, Indianapolis, Indiana, 46202, United States|Pfizer Investigational Site, Boston, Massachusetts, 02114, United States|Pfizer Investigational Site, Boston, Massachusetts, 02115, United States|Pfizer Investigational Site, Boston, Massachusetts, 02215, United States|Pfizer Investigational Site, Ann Arbor, Michigan, 48109-0843, United States|Pfizer Investigational Site, Detroit, Michigan, 48201, United States|Pfizer Investigational Site, Farmington Hills, Michigan, 48334, United States|Pfizer Investigational Site, Minneapolis, Minnesota, 55455-0392, United States|Pfizer Investigational Site, St. Louis, Missouri, 63110, United States|Pfizer Investigational Site, Albuquerque, New Mexico, 87131-0001, United States|Pfizer Investigational Site, Albuqurque, New Mexico, 87106, United States|Pfizer Investigational Site, New York, New York, 10021, United States|Pfizer Investigational Site, New York, New York, 10022, United States|Pfizer Investigational Site, New York, New York, 10032, United States|Pfizer Investigational Site, Durham, North Carolina, 27710, United States|Pfizer Investigational Site, Cleveland, Ohio, 44195, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, 19111, United States|Pfizer Investigational Site, Myrtle Beach, South Carolina, 29572, United States|Pfizer Investigational Site, Franklin, Tennessee, 37067, United States|Pfizer Investigational Site, Gallatin, Tennessee, 37066, United States|Pfizer Investigational Site, Hermitage, Tennessee, 37076, United States|Pfizer Investigational Site, Lebanon, Tennessee, 37087, United States|Pfizer Investigational Site, Murfreesboro, Tennessee, 37130, United States|Pfizer Investigational Site, Nashville, Tennessee, 37203, United States|Pfizer Investigational Site, Nashville, Tennessee, 37205, United States|Pfizer Investigational Site, Nashville, Tennessee, 37207, United States|Pfizer Investigational Site, Nashville, Tennessee, 37211, United States|Pfizer Investigational Site, Nashville, Tennessee, 37212, United States|Pfizer Investigational Site, Nashville, Tennessee, 37232, United States|Pfizer Investigational Site, Smyrna, Tennessee, 37167, United States|Pfizer Investigational Site, Dallas, Texas, 75246, United States|Pfizer Investigational Site, Houston, Texas, 77030-4009, United States|Pfizer Investigational Site, Madison, Wisconsin, 53792, United States|Pfizer Investigational Site, Randwick, New South Wales, 2031, Australia|Pfizer Investigational Site, East Melbourne, Victoria, 3002, Australia|Pfizer Investigational Site, Heidelberg, Victoria, 3084, Australia|Pfizer Investigational Site, Montreal, Quebec, H2L 4M1, Canada|Pfizer Investigational Site, Villejuif Cedex, 94805, France|Pfizer Investigational Site, Thessaloniki, 564 03, Greece|Pfizer Investigational Site, Milano, 20133, Italy|Pfizer Investigational Site, Milano, 20141, Italy|Pfizer Investigational Site, Nijmegen, Gld, 6525 GA, Netherlands|Pfizer Investigational Site, Singapore, 308433, Singapore|Pfizer Investigational Site, Lund, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, St. Gallen, CH-9007, Switzerland|Pfizer Investigational Site, Leeds, LS9 7TF, United Kingdom|Pfizer Investigational Site, London, NW1 2PG, United Kingdom|Pfizer Investigational Site, London, SW3 6JJ, United Kingdom|Pfizer Investigational Site, Newcastle-Upon-Tyne, NE4 6BE, United Kingdom Less <<
NCT00589784 CNS Cancer|Meningioma|Intracra... More >>nial Hemangiopericytoma|Hemangioblastoma|Neurofibromatosis Less << PHASE2 COMPLETED 2025-10-14 Dana Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States|Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, 11725, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, 10065, United States|University of Pittsburgh Medical Center, Pittsburg, Pennsylvania, United States|University of Virginia Health Science Center, Charlottesville, Virginia, 22908, United States Less <<
NCT01216657 Chemo-refractory Melanoma PHASE2 TERMINATED 2025-05-13 Krankenhaus Nordwest, Frankfur... More >>t/Main, 60488, Germany Less <<
NCT00089648 Carcinoma, Renal Cell PHASE2 COMPLETED 2025-03-08 Pfizer Investigational Site, D... More >>uarte, California, 91010, United States|Pfizer Investigational Site, Pasadena, California, 91105, United States|Pfizer Investigational Site, San Francisco, California, 94115, United States|Pfizer Investigational Site, Chicago, Illinois, 60637-1460, United States|Pfizer Investigational Site, Boston, Massachusetts, 02114, United States|Pfizer Investigational Site, Boston, Massachusetts, 02115, United States|Pfizer Investigational Site, Boston, Massachusetts, 02215, United States|Pfizer Investigational Site, Durham, North Carolina, 27710, United States|Pfizer Investigational Site, Cleveland, Ohio, 44195, United States|Pfizer Investigational Site, Nashville, Tennessee, 37232-5536, United States|Pfizer Investigational Site, Dallas, Texas, 75246, United States Less <<
NCT01824615 Ovarian Cancer|Adverse Effects PHASE2 COMPLETED 2025-01-16 Cathay General Hospital, Taipe... More >>i, 106, Taiwan Less <<
NCT00843037 Paraganglioma|Pheochromocytoma PHASE2 COMPLETED 2022-03-14 Tom Baker Cancer Centre, Calga... More >>ry, Alberta, T2N 4N2, Canada|University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada|H?pital Notre-Dame du CHUM, Montreal, Quebec, H2L 4M1, Canada|University Medical Centre Groningen, Groningen, Netherlands Less <<
NCT00599313 Metastatic Prostate Cancer PHASE2 COMPLETED 2025-06-09 Hematology Oncology Associates... More >>, Phoenix, Arizona, 85012, United States|Connecticut Oncology & Hematology, LLP, Torrington, Connecticut, 06790, United States|Ocala Oncology Center, Ocala, Florida, 34474, United States|Cancer Care & Hematology Specialista of Chicagoland, Niles, Illinois, 60714, United States|Hope Center, Terre Haute, Indiana, 47802, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, 21044, United States|Alliance Hematology Oncology PA, Westminster, Maryland, 21157, United States|Missouri Cancer Associates, Columbia, Missouri, 65201, United States|St. Joseph Oncology, Inc., Saint Joseph, Missouri, 64507, United States|Arch Medical Services, Inc. DBA The Cntr for Cancer Care & Research, Saint Louis, Missouri, 63141, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|NH Oncology-Hematology PA, Hooksett, New Hampshire, 03106, United States|New Mexico Cancer Care Associates, Santa Fe, New Mexico, 87505, United States|New York Oncology Hematology, P.C., Albany, New York, 12206, United States|Interlakes Oncology Hematology, PC, Rochester, New York, 14623, United States|Cancer Centers of North Carolina, Raleigh, North Carolina, 27607, United States|Greater Dayton Cancer Center, Kettering, Ohio, 45409, United States|Medical Oncology Associates, Kingston, Pennsylvania, 18704, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, 29605, United States|Texas Cancer Center-Abilene(South), Abilene, Texas, 79606, United States|Texas Oncology, P.A.-Amarillo, Amarillo, Texas, 79106, United States|Texas Cancer Center, Arlington, Texas, 76014, United States|Texas Oncology Cancer Center, Austin, Texas, 78731, United States|Mamie McFaddin Ward Cancer Center, Beaumont, Texas, 77702, United States|Texas Oncology, P.A.-Bedford, Bedford, Texas, 76022, United States|Texas Cancer Center at Medical City, Dallas, Texas, 75230, United States|Texas Onclogy, P.A., Dallas, Texas, 75231, United States|Methodist Charlton Cancer Ctr., Dallas, Texas, 75237, United States|Texas Oncology, P.A., Dallas, Texas, 75246, United States|Texas Cancer Center, Denton, Texas, 76210, United States|El Paso Cancer Treatment Ctr, El Paso, Texas, 79915, United States|Texas Oncology, P.A., Fort Worth, Texas, 76104, United States|Allison Cancer Center, Midland, Texas, 79701, United States|Texas Oncology-Odessa, Odessa, Texas, 79761, United States|Paris Regional Cancer Center, Paris, Texas, 75460, United States|HOAST-Medical Dr., San Antonio, Texas, 78229, United States|Texas Oncology Cancer Center-Sugar Land, Sugar Land, Texas, 77479, United States|Texas Oncology Cancer Care and Research, Waco, Texas, 76712, United States|Texas Oncology, P.A., Webster, Texas, 77598, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Onc and Hem Associates of SW VA, Inc., Salem, Virginia, 24153, United States|Puget Sound Cancer Center-Edmonds, Edmonds, Washington, 98026, United States|Puget Sound Cancer Center-Seattle, Seattle, Washington, 98133, United States|Northwest Cancer Specialists-Vancouver, Vancouver, Washington, 98684, United States|Yakima Valley Mem Hosp/North Star Lodge, Yakima, Washington, 98902, United States Less <<
NCT01499121 Clear Cell, Metastatic Renal C... More >>ell Carcinoma Less << PHASE2 COMPLETED 2017-09-30 Tom Baker Cancer Centre, Calga... More >>ry, Alberta, T2N 4N2, Canada|Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada|BC Cancer Agency - Vancouver, Vancouver, British Columbia, V5Z 4E6, Canada|CancerCare Manitoba, Winnipeg, Manitoba, R3E 0V9, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, B3H 3A7, Canada|Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|Kingston General Hospital Research Institute, Kingston, Ontario, K7L 2V7, Canada|London Health Sciences Centre, London, Ontario, N6A 4L6, Canada|Durham Regional Cancer Centre, Oshawa, Ontario, L1G 2B9, Canada|Ottawa Hospital Cancer Centre, Ottawa, Ontario, K1H 8L6, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|Notre-Dame Hospital, Montreal, Quebec, H2W 1T8, Canada Less <<
NCT00663559 Carcinoma Renal Cells PHASE2 COMPLETED 2025-02-10 Hospital Central de Asturias, ... More >>Oviedo, Asturias, 33006, Spain|Hospital Parc Taulí, Sabadell, Barcelona, 08208, Spain|Hospital CLINIC, Barcelona, 08036, Spain|Hospital Reina Sofía, Córdoba, 14004, Spain|Hospital de Jaén, Jaén, 23007, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital lozano Blesa, Zaragoza, 50009, Spain Less <<
NCT01033981 Metastatic Renal Cell Carcinom... More >>a Less << TERMINATED 2025-02-11 Pfizer Investigational Site, P... More >>anama City, Panama Less <<
NCT01168440 Von Hippel-Lindau Disease PHASE2 COMPLETED 2025-02-11 Hospital Saint André - Service... More >> de cancérologie, Bordeaux, 33075, France|Hopital Kremlin-Bicêtre, Kremlin-Bicêtre, 94275, France|H?pital Européen Georges Pompidou - Service d'Oncologie Médicale, Paris, 75015, France Less <<
NCT00768144 Ovarian Cancer|Fallopian Tube ... More >>Cancer|Peritoneal Cancer Less << PHASE2 COMPLETED 2025-02-13 Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02115, United States|Massachusetts General Hospital, Boston, Massachusetts, 02214, United States|Beth-Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States Less <<
NCT00510640 Cancer|Thyroid Carcinoma PHASE2 COMPLETED 2025-03-12 Centre Paul Papin - 2 rue Moll... More >>, Angers, 49100, France|Département Endocrinolo-Diabéto-Nutrition - CHU d'Angers - 4 rue de Larray, Angers, 49933, France|Service d'Oncologie Médicale et de Radiothérapie - H?pital Saint André - 1 rue Jean Burguet, Bordeaux, 33075, France|Fédération Endocrinologie - Groupe Hospitalier Est - H?pital neurologique - CHU Lyon - 59 Boulevard Pinel, Bron, 69677, France|Service d'Endocrinologie et maladies métaboliques, Clinique Marc Linquette - rue du Pr Laguesse, Lille, 59037, France|Centre Léon Bérard - Département de Médecine - 28 rue Laennec, Lyon, 69373, France|Service d'Endocrinologie, CHU Timone, AP-HM - 254 rue St Pierre, Marseille, 13385, France|Service des Maladies Endocriniennes - H?pital Lapeyronie - 191 avenue du Doyen Gaston Giraud, Montpellier, 34295, France|Centre Paul Lamarque - Va d'Aurelle - CRLC Val d'Aurelle - 208 rue des Apothicaires, Montpellier, 34298, France|Centre Antoine Lacassagne - 33 avenue de Valombrose, Nice, 06189, France|Service d'Endocrinologie - H?pital de l'Archet I - Route Saint Antoine de Jinestière, Nice, 06202, France|Service de Cancérologie Médicale - HEGP - 20 rue Leblanc, Paris, 75015, France|Service d'Oncologie Médicale, Institut Claudius Regaud - 20-24 rue du Pont Saint Pierre, Toulouse, 31052, France|Service d'endocrinologie et Maladies Métaboliques, Groupe Hospitalier Rangueil-Larrey CHU Toulouse - avenue Prof Jean Poulhes, Toulouse, 31059, France|Service d'Endocrinologie - CHU de Nancy, H?pital de Brabois - rue du Morvan, Vandoeuvre les Nancy, 54511, France Less <<
NCT02398552 Metastatic Renal Cell Carcinom... More >>a Less << PHASE2 UNKNOWN 2025-03-17 Chinese acadamy of medical sci... More >>ence cancer institute & hospital, Beijing, Beijing, 100021, China|Peking University First Hospital, Beijing, Beijing, 100034, China|Beijing Cancer Hospital, Beijing, Beijing, 100142, China|Sun Yat-sen university cancer center, Guangzhou, Guangdong, 510060, China|Cancer Hospital, Fudan University, Shanghai, Shanghai, 200032, China|Tianjin medical university cancer institute & hospital, Tianjin, Tianjin, 300060, China Less <<
NCT03066427 Clear Cell Renal Carcinoma PHASE2 COMPLETED 2020-09-22 ICO Duran i Reynals, L'Hospita... More >>let de Llobregat, Barcelona, 08908, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, 08036, Spain|Complejo Hospitalario Regional Reina Sofía, Córdoba, 14004, Spain|Hospital Ramón Y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Centro Integral Oncologico Clara Campal, Madrid, Spain|MD Anderson Cancer Center Madrid, Madrid, Spain|Hospital Central de Asturias, Oviedo, Spain Less <<
NCT01219751 Metastatic Renal Cell Carcinom... More >>a Less << PHASE2 UNKNOWN 2025-09-11 Asan Medical Center, Seoul, 13... More >>8-736, Korea, Republic of Less <<
NCT04115189 Metastatic Renal Cell Carcinom... More >>a ( mRCC) Less << COMPLETED 2020-12-02 Instituto Médico Especializado... More >> Alexander Fleming, Buenos Aires, Argentina|Sanatorio del Salvador - Cordoba, Cordoba, Argentina|Centro Oncológico de Integración Regional in Mendoza, Mendoza, M5500AYB, Argentina|Escola Paulista de Medicina - UNIFESP, S?o Paulo, Brazil|Fundacion Cardiovascular de Colombia, Bogotá, Colombia|Sociedad de Oncologia y Hematologia Del Cesar ltda (SOHEC), Valledupar, Colombia|Hospital Eugenio Espejo, Quito, Ecuador Less <<
NCT00794950 Urinary Tract Urothelial Carci... More >>noma Less << PHASE2 COMPLETED 2016-08-22 Mark P. Schoenberg, MD, Baltim... More >>ore, Maryland, 21287-2101, United States|Alon Weizer, MD, Ann Arbor, Michigan, 48109, United States Less <<
NCT05745142 Carcinoma, Renal Cell|Clear-ce... More >>ll Metastatic Renal Cell Carcinoma Less << COMPLETED 2023-02-23 Pfizer, Istanbul, 34394, Turke... More >>y Less <<
NCT02058901 Solid Tumors PHASE1 COMPLETED 2025-06-19 VU University Medical Center, ... More >>Amsterdam, 1081HV, Netherlands Less <<
NCT02691793 Refractory Solid Tumors PHASE4 COMPLETED 2019-11-19 Samsung Medical Center, Seoul,... More >> Seoul, Korea, Republic Of, 135-710, Korea, Republic of Less <<
NCT00783653 Acute Myeloid Leukemia PHASE1|PHASE2 COMPLETED - Prof. Dr. med. Walter Fiedler,... More >> Hamburg, 20246, Germany|PD Dr. med. Jürgen Krauter, Hannover, 30625, Germany|Dr. Katharina G?tze, München, 81675, Germany|Prof. Dr. Helmut R. Salih, Tübingen, 72076, Germany|Dr. Richard Schlenk, Ulm, 89081, Germany Less <<
NCT02689167 Kidney Neoplasms|Metastatic Re... More >>nal Cell Cancer Less << PHASE2 UNKNOWN 2025-02-24 CHU Besancon, Besancon, Franch... More >>e-Comté, 25030, France Less <<
NCT04368546 Renal Cell Cancer Metastatic|H... More >>ypertension|Sodium Imbalance Less << COMPLETED 2020-03-01 Experimental and Clinical Rese... More >>arch Center, Clinical Research Unit, Berlin, 13125, Germany Less <<
NCT00796861 Ascites PHASE2 TERMINATED 2025-04-11 Penn State Milton S. Hershey M... More >>edical Center, Hershey, Pennsylvania, 17033, United States Less <<
NCT02713763 Pancreatic Neuroendocrine Tumo... More >>ur Metastatic Less << PHASE2 COMPLETED 2019-10-23 Hospital Universitario Central... More >> de Asturias, Oviedo, Asturias, 33011, Spain|Hospital Universitario Valle de Hebrón, Barcelona, 08035, Spain|Hospital Reina Sofía, Córdoba, 14004, Spain|Hospital Universitario Donostia, Donostia/San Sebastián, 20014, Spain|Hospital Ramón y Cajal, Madrid, 28034, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital General Universitario J.M. Morales Meseguer, Murcia, 30008, Spain|Complejo Hospitalario Regional Virgen Del Rocío, Sevilla, 41013, Spain|Instituto Valenciano de Oncología, Valencia, 46009, Spain Less <<
NCT03449173 Type B3 Thymoma|Thymic Carcino... More >>ma Less << PHASE2 UNKNOWN 2022-05-31 National Cancer Institute, Mil... More >>an, 20133, Italy Less <<
NCT00453895 Adrenocortical Carcinoma PHASE2 COMPLETED 2025-02-12 Charite Berlin, Berlin, German... More >>y|Dept. of Medicine I, University of Wuerzburg, Wuerzburg, 97080, Germany Less <<
NCT00092001 Carcinoma, Non-Small-Cell Lung PHASE2 COMPLETED 2025-03-07 Pfizer Investigational Site, B... More >>altimore, Maryland, 21231-1000, United States|Pfizer Investigational Site, St. Louis, Missouri, 63110-1094, United States|Pfizer Investigational Site, St. Louis, Missouri, 63110, United States|Pfizer Investigational Site, St. Peters, Missouri, 63376, United States|Pfizer Investigational Site, Chapel Hill, North Carolina, 27599-7600, United States|Pfizer Investigational Site, Clinton, North Carolina, 28382, United States|Pfizer Investigational Site, Goldsboro, North Carolina, 27534, United States|Pfizer Investigational Site, Pollocksville, North Carolina, 28573, United States|Pfizer Investigational Site, Wilson, North Carolina, 27893, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, 15232, United States|Pfizer Investigational Site, Charlottesville, Virginia, 22908, United States|Pfizer Investigational Site, Orbassano (Torino), 10043, Italy|Pfizer Investigational Site, Badalona, Barcelona, 08916, Spain|Pfizer Investigational Site, Barcelona, 08025, Spain Less <<
NCT01042795 Urothelial Carcinoma|Bladder C... More >>ancer Less << PHASE2 TERMINATED 2025-01-13 University of Michigan, Ann Ar... More >>bor, Michigan, 48109, United States Less <<
NCT01034878 Carcinoma, Renal Cell PHASE2 COMPLETED 2025-12-14 Istituto Clinco Humanitas, Roz... More >>zano, Milano, 20089, Italy Less <<
NCT00226811 Stomach Neoplasms PHASE2 COMPLETED 2025-05-08 Pfizer Investigational Site, N... More >>anjing, Jiangsu, 210002, China|Pfizer Investigational Site, Beijing, 100036, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Guangzhou, 510515, China|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Ancona, 60020, Italy|Pfizer Investigational Site, Genova, 16132, Italy|Pfizer Investigational Site, Kashiwa, Chiba, Japan|Pfizer Investigational Site, Suntougun, Shizuoka, Japan|Pfizer Investigational Site, Chuo-ku, Tokyo, Japan|Pfizer Investigational Site, Seoul, 110-744, Korea, Republic of|Pfizer Investigational Site, Seoul, 120-752, Korea, Republic of|Pfizer Investigational Site, Seoul, 135-710, Korea, Republic of|Pfizer Investigational Site, Seoul, 138-736, Korea, Republic of|Pfizer Investigational Site, Porto, 4200-072, Portugal|Pfizer Investigational Site, Kwei-Shan, Taoyuan, 333, Taiwan|Pfizer Investigational Site, Taipei, 100, Taiwan Less <<
NCT00886132 Adenoid Cystic Carcinoma|Saliv... More >>ary Gland Cancer Less << PHASE2 COMPLETED 2025-12-12 Princess Margaret Hospital, To... More >>ronto, Ontario, M5G 2M9, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.51mL

0.50mL

0.25mL

12.55mL

2.51mL

1.25mL

25.10mL

5.02mL

2.51mL

References

 

Historical Records

Categories